Abstract Human chorionic gonadotropin (hCG) is a heterodimer consisting of an α- and a β-subunit (hCGα and hCGβ) that are non-covalently linked. Intact hCG, but not free subunits, bind to the LH/hCG receptor. Expression of hCG and hCGβ has been observed in several cancers. Most trophoblastic tumors of placental and germ cell origin produce hCG, while many non-trophoblastic tumors, including bladder, renal and gastrointestinal cancers, often produce hCGβ, and increased serum concentrations of these are associated with adverse prognosis. hCG has been found to stimulate trophoblast invasion. The stimulatory activity has especially been ascribed to a hyperglycosylated form of hCG (hCG-h) expressed in early pregnancy. hCG-h is also a major form of hCG produced by choriocarcinoma and by testicular cancers, although tumor-derived hCG-h is often glycosylated differently than that produced by the placenta. We aimed to compare different forms of hCG in their stimulatory activities on the invasion of JEG-3 choriocarcinoma cells. Various forms of hCG and hCGβ were purified from urine of one patient with nonseminomatous testicular cancer, one with invasive molar disease, and pregnant women. Both hCG and hCGβ, and their hyperglycosylated forms stimulated the invasion of JEG-3 cells. However, cancer-derived hCG-h was more effective than “regular” hCG in stimulating the invasion. Down-regulation of the LH/hCG receptor by RNA-interference did not significantly reduce the effect of hCGβ and hCG on cell invasion. Increased invasion was associated with increased activity of MMP-2, MMP-9 and uPA in conditioned culture medium from JEG-3 cells. Our findings suggest that hCG and hCGβ stimulates the invasion of choriocarcinoma cells independent of the classical LH/hCG-receptor. Citation Format: Cheuk-Lun Lee, Philip CN Chiu, Laura Hautala, William SB Yeung, Ulf-Håkan Stenman, Hannu Koistinen. Free β-subunit of human chorionic gonadotropin stimulates choriocarcinoma cell invasion independent of LH/hCG receptor. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4938. doi:10.1158/1538-7445.AM2013-4938
Read full abstract